In vitro susceptibility pattern of Tigecycline against MRSA, ESBL producing Escherichia coli, Klebsiella species and Acinetobacter isolates in a rural tertiary care hospital.

Simple item page
dc.contributor.authorNandi, P
dc.contributor.authorKumar, S
dc.contributor.authorBiswas, T
dc.contributor.authorMitra, G
dc.contributor.authorChejara, SK
dc.contributor.authorRoy, S
dc.date.accessioned2016-11-07T09:58:00Z
dc.date.available2016-11-07T09:58:00Z
dc.date.issued2015-01
dc.description.abstractBackground: Tigecycline is the first commercially available glycycline, derivatives of the tetracycline antibiotics, having enhanced activity against various pathogens. In vitro activity has been demonstrated against multi drug resistant Gram positive and Gram negative pathogens like MRSA, ESBL producing Esch.coli and Klebsiella spp. and Acinetobacter Objective: To determine Tigecycline in vitro susceptibility pattern in MRSA, ESBL producing Esch.coli and Klebsiella spp. and Acinetobacter spp. Material and Methods: Investigations were carried out from August 2012-January 2014 to detect MRSA,ESBL producing Escherichia coli and Klebsiella spp. as well as Acinetobacter spp. by using a standard protocols and Tigecycline in-vitro susceptibility testing was done by Kirby Bauer Disc diffusion method and it’s MIC value against resistant isolates was evaluated.Statistical analysis was done by Fishers extract method. Result: Out of 107 Staphylococcus aureus isolates 52(48.59%) were MRSA, none of them showed resistance to Tigecycline. Out of 82 Esch.coli isolates 14 (i.e 17.07%) were ESBL producers, none of them showed resistance to Tigecycline.Out of 67 Klebsiella isolates 21 (i.e 31.34%) were ESBL producers out of which only 1 (i.e 4.76%) was resistant to Tigecycline.Out of 19 Acinetobacter spp.isolated 3 (i.e 15.78%) were resistant to Tigecycline. The MIC range for ESBL producing Eschcoli, Klebsiella spp., MRSA and acinetobacter spp were 0.14-0.45 μg/ml,0.25-2.4 μg/ml,0.12-0.26 μg/ml, 1-3.2 μg/ml respectively. Conclusion: The results of the study confirm the excellent in vitro activity of Tigecycline against Gram positive and Gram negative multidrug resistant pathogens.en_US
dc.identifier.citationNandi P, Kumar S, Biswas T, Mitra G, Chejara SK, Roy S. In vitro susceptibility pattern of Tigecycline against MRSA, ESBL producing Escherichia coli, Klebsiella species and Acinetobacter isolates in a rural tertiary care hospital. International Journal of Medical and Dental Sciences. 2015 Jan; 4(1): 607-617.en_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/178275
dc.language.isoenen_US
dc.source.urihttps://ijmds.org/wp-content/uploads/2014/12/607-617OAV4.pdfen_US
dc.subjectTigecyclineen_US
dc.subjectsusceptibilityen_US
dc.subjectMRSAen_US
dc.subjectESBL producing Klebsiella sppen_US
dc.subjectacinetobacteren_US
dc.titleIn vitro susceptibility pattern of Tigecycline against MRSA, ESBL producing Escherichia coli, Klebsiella species and Acinetobacter isolates in a rural tertiary care hospital.en_US
dc.typeArticleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
ijmds2015v4n1p607.pdf
Size:
731.31 KB
Format:
Adobe Portable Document Format
Description:
Original article
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
International Journal of Medical and Dental Sciences